cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1456Research ArticleОБЗОРЫREVIEWSКомбинированная антигипертензивная терапия у больных с высоким риском развития сердечно-сосудистых осложненийCombined antihypertensive in patients with high risk of cardiovascular eventshttps://orcid.org/сахарный диабет; комбинированная терапия; прогнозКарповЮ. А.KarpovYu. A.

Директор.

Москва, тел.: (495) 415-52-05

Moscow

karpov.cardio@mtu-net.ruИнститут клинической кардиологии им. А.Л.Мясникова, ФГУ Российский кардиологический научно-производственный комплекс РосмедтехнологииA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies20092006200983103109Copyright © Карпов Ю.А., 20092009Карпов Ю.А.Karpov Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1456

The article is devoted to the issue of optimizing blood pressure control in the patients with Type 2 diabetes mellitus, with or without arterial hypertension, by antihypertensive therapy with a fixed combination of low doses of perindopril and indapamide. Such therapeutic approach is consistent with the basic principles of cardiovascular risk stratification and facilitates prognosis improvement.

сахарный диабеткомбинированная терапияпрогнозdiabetes mellituscombined therapyprognosisReferencesРоссийское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваск тер профил 2008; 6(Приложение 2).Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваск тер профил 2008; 6(Приложение 2).The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007; 28: 88-136.The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007; 28: 88-136.The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.Yusuf S, Diener H-C, Sacco RL, et al. for the PRoFESS study group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359.Yusuf S, Diener H-C, Sacco RL, et al. for the PRoFESS study group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359.PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-41.PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-41.ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828-40.ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828-40.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderty Program (SHEP). JAMA 1991; 265: 3255-64.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderty Program (SHEP). JAMA 1991; 265: 3255-64.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin—converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981—97.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin—converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981—97.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805—16.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805—16.Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995—1003.Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995—1003.Dahlof B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895—906.Dahlof B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895—906.Hansson L, Zanchetti JA, Carruthers SG. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755—62.Hansson L, Zanchetti JA, Carruthers SG. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755—62.Amar J, Vaur L, Perret M, et al. Hypertension in high-risk patients: beware of the uderuse of effective combination therapy (results of the PRATIC study). J Hypertens 2002; 20: 79—84.Amar J, Vaur L, Perret M, et al. Hypertension in high-risk patients: beware of the uderuse of effective combination therapy (results of the PRATIC study). J Hypertens 2002; 20: 79—84.Mogensen CE, Viberti G, Halimi S, et al. Preterax in Albuminuria Regression (PREMIER) Study Groupe. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003; 41: 1063—71.Mogensen CE, Viberti G, Halimi S, et al. Preterax in Albuminuria Regression (PREMIER) Study Groupe. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003; 41: 1063—71.London GM, Asmar RG, O’ Rourke MF, et al., on behalf of the REASON Project coordinators and ivestigators. Mechanism (s) of selective systolic blood pressure reduction after a lowdose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. JACC 2004; 43: 92—9.London GM, Asmar RG, O’ Rourke MF, et al., on behalf of the REASON Project coordinators and ivestigators. Mechanism (s) of selective systolic blood pressure reduction after a lowdose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. JACC 2004; 43: 92—9.Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23: 2063—70.Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23: 2063—70.Adler A, Stratton IM, Neil H, et al. Assotiation of systolic blood pressure with macrovascular and microvascular compli¬cations of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412—9.Adler A, Stratton IM, Neil H, et al. Assotiation of systolic blood pressure with macrovascular and microvascular compli¬cations of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412—9.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 dia¬betes: UKPDS 38. Br Med J 1998; 317: 703—13.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 dia¬betes: UKPDS 38. Br Med J 1998; 317: 703—13.The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabe¬tes. N Engl J Med 2008; 358: 2560—72.The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabe¬tes. N Engl J Med 2008; 358: 2560—72.Chalmers J. ADVANCE: new results. EASD 2008 Meeting, September 8. Oral presentation.Chalmers J. ADVANCE: new results. EASD 2008 Meeting, September 8. Oral presentation.

The authors declare that there are no conflicts of interest present.